Source: Annual Congress 2008 - Airway cell biology and immunology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Popper, H. Kothmaier, I. Halbwedl (Graz, Austria). Experimental target therapy in mesothelioma cells. Eur Respir J 2008; 32: Suppl. 52, 3596

Member's Comments

No comment yet.

Related content which might interest you: Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Satisfractory therapeutic effects of EGFR-TK treatment of a malignant mesothelioma of the pleura: a case report Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 BAP1 expression and treatment outcomes in malignant mesothelioma. Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017